CONTENTS
Contents 5.
How to streamline a complex process: why experienced medical writers will add value to oncology dossiers Getting approval for new drugs can be complicated. Trilogy Writing & Consulting reveals how medical writers can help
7. 8.
Chapter 1: Clinical development in oncology
As Russia’s clinical trial sector falls, Ukraine rebuilds The impact of the war on the clinical trial landscapes of Ukraine and Russia
13.
Biden reignites Moonshot programme with goal to halve cancer How Joe Biden’s Cancer Moonshot initiative could benefit oncology research
14.
COVID-19 two years on: persistent symptoms of clinical trial disruption trouble certain therapy areas A deep dive into which therapeutic areas are recovering as we enter a post-pandemic trial space
18.
Empower your next study with a truly unified system Six key advantages of a unified, robust modular approach over separate systems
20. 21.
Chapter 2: Immunotherapy
Targeting the tumour stroma interface to overcome immunotherapy resistance Catherine Pickering, CEO of iOnctura, discusses the Swiss biotech’s advances in cancer therapies
4 | 37.
32. 33.
23.
Tracking the rise of CAR-Ts in China: the dawn of an immunotherapy superpower? How China appears to be surpassing its Western counterparts in building a pipeline of CAR-T therapies
28.
Cell and gene therapy society establishes working group to tackle expanded access misuse The ISCT Expanded Access Group’s role within the unapproved CGT sector
29.
The Opdualag effect: designing first-line melanoma clinical trials after anti-LAG-3 approval Why FDA approval of Opdualag is likely to influence forthcoming data read-outs and active comparator choices in trials
Chapter 3: Patient-centricity in oncology trials
Fertility impact questions as breast cancer clinical trials recruit younger patients How additional study design parameters could measure and alleviate fertility risk
35.
ASCO GU: many kidney cancer patients left out of clinical trial discussions New survey reveals the barriers to accessing clinical trials
Trial diversity: it’s time to quit talking and start doing The efforts in the US to improve diversity in clinical trials
40. Suppliers’ directory
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
